Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Redx Pharma Plc RNS Release

Preclinical efficacy data presented on RXC005

RNS Number : 0714F
Redx Pharma plc
15 May 2017
 

15 May 2017

AIM: REDX

Abstract #219

Poster #210

 

REDX PHARMA PLC

("Redx" or "the Company")

 

Preclinical data for reversible BTK inhibitor RXC005 presented at the 17th International Workshop of Chronic Lymphocytic Leukemia  

 

Redx Pharma, the research and development company focused on cancer, immunology and infection, announces that preclinical efficacy data in mouse-models for its development candidate, RXC005, a reversible BTK inhibitor, has been presented in a poster session at the 17th International Workshop of Chronic Lymphocytic Leukemia (iwCLL) biennial meeting in New York City, U.S. on 14 May, 2017.

 

The poster, entitled "RXC005, a Potent and Selective, Reversible BTK Inhibitor Targeting both Wild-type and Mutant C481S BTK with Potent Efficacy in ABC-DLBCL Xenograft Mouse Models", demonstrated that RXC005 successfully inhibits wild-type BTK and C481S mutant BTK, as well as B-Cell Receptor signalling in ABC-DLBCL cell lines and importantly primary CLL cells.

 

RXC005 was also shown to be highly selective and exhibits improved target specificity against other Tec and Src kinase family members. RXC005 demonstrated significant efficacy in ABC-DLBCL xenograft mouse models such as TMD8 and OCI-Ly10 cell lines.

The poster can be found on the Company's website www.redxpharma.com

Dr Neil Murray, Chief Executive Officer of Redx Pharma, commented: "We are delighted to have presented further potent efficacy data for one of our lead development candidates, RXC005, at the prestigious iwCLL event in front of our peers and contemporaries."

 

Dr Richard Armer, Chief Scientific Officer of Redx Pharma, commented: "The data presented is further validation of RXC005's potential to target both wild-type and mutant BTK, an important emerging resistance mechanism in patients with CLL progression following ibrutinib treatment. With good target engagement demonstrated in the PK/PD studies and efficacy in mouse-models, we look forward to filing an IND/CTA in late 2017 to take RXC005 into the clinic."

 

For further information, please contact:

Redx Pharma Plc


Neil Murray, Chief Executive Officer

T: +44 1625 469 900 

Karl Hård, Head of IR & Corporate Communications

 

T: +44 7491 651 406

Cantor Fitzgerald Europe (Nomad & Broker)

T: +44 20 7894 7000

Phil Davies/ Michael Reynolds

 



WG Partners LLP (Joint Broker)

T: +44 20 3705 9330

Claes Spång/ Chris Lee/ David Wilson

 

 

Consilium Strategic Communications

 

T: +44 20 3709 5700

Amber Fennell/ Matthew Neal/ Melissa Gardiner


 

 

About Redx Pharma Plc

Company website: www.redxpharma.com 

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, immunology and infection providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a broad portfolio of proprietary drug programs.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAAIMBTMBBBTAR



Redx Pharma Plc Timeline

CN Research
April 06 2017

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use